Table 1.
Major studies evaluating the effects of glucagon-like peptide-1 (GLP-1) receptor agonists on obesity in patients with polycystic ovary syndrome.
| Reference | GLP-1 Agonist | n | Follow-Up (Weeks) |
Baseline Body Mass Index (kg/m2) |
Lifestyle Intervention | Metformin Treatment | Main Results |
|---|---|---|---|---|---|---|---|
| [35] | Liraglutide 1.2–1.8 mg/day | 65 | 26 | 33.3 | No | No | Greater reduction in body weight than placebo |
| [36] | Liraglutide 1.2 mg/day | 28 | 12 | 39.5 | No | Comparator arm | Similar weight loss with metformin |
| [40] | Liraglutide 3.0 mg/day | 67 | 32 | 42.7 | Diet and exercise | No | 57% experienced ≥5% weight loss compared with 22% in the placebo group |
| [41] | Liraglutide 3.0 mg/day | 28 | 12 | 38.3 | Diet and exercise | Comparator arm | Greater reduction in body mass index and waist circumference and waist circumference than metformin 1000 mg bid and liraglutide 1.2 mg/day |